11 Best NASDAQ Stocks Under $5 to Buy Now

Page 8 of 10

3. Taysha Gene Therapies Inc. (NASDAQ:TSHA)

Share Price as of October 23: $4.94

Number of Hedge Fund Holders: 34

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best NASDAQ stocks under $5 to buy now. On October 16, Taysha Gene Therapies announced that it had regained full global rights to its lead program, TSHA-102, which is in clinical evaluation for the treatment of Rett syndrome. The 2022 Option Agreement between Taysha and Astellas has officially expired.

The agreement granted Astellas an exclusive option to negotiate an exclusive license to TSHA-102 for Rett syndrome. Taysha now holds unencumbered rights to the program, granting the company full strategic flexibility and optionality to drive long-term value.TSHA-102 Clinical Data and Regulatory StatusTaysha had delivered a TSHA-102 data package to Astellas in mid-2025, which contained the previously disclosed Part A REVEAL Phase 1/2 clinical data (with a May 2025 data cutoff).

TSHA-102 MechanismTSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy designed as a one-time treatment. It addresses the genetic root cause of Rett syndrome by delivering a functional form of the MECP2 gene to CNS cells. The therapy uses a novel miRNA-Responsive Auto-Regulatory Element/miRARE technology, which is engineered to mediate MECP2 levels in the CNS on a cell-by-cell basis without the risk of overexpression.

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company that develops and commercializes adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.

Page 8 of 10